Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.52 - $3.63 $193,536 - $278,784
-76,800 Reduced 71.98%
29,900 $92,000
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $185,093 - $239,148
81,900 Added 330.24%
106,700 $275,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $2,704 - $4,064
1,600 Added 6.9%
24,800 $62,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $2.27 $1,900 - $2,270
-1,000 Reduced 4.13%
23,200 $47,000
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $27,104 - $37,026
12,100 Added 100.0%
24,200 $55,000
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $122,873 - $170,810
-55,100 Reduced 81.99%
12,100 $36,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $30,178 - $45,030
15,800 Added 30.74%
67,200 $156,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $25,192 - $38,592
-13,400 Reduced 20.68%
51,400 $98,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $546M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.